To compare the effects of Dabigatran,Rivaroxaban and Apixaban on plasma fibrinolysis in patients with non valvular atrial fibrillation

Trial Profile

To compare the effects of Dabigatran,Rivaroxaban and Apixaban on plasma fibrinolysis in patients with non valvular atrial fibrillation

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Dec 2016

At a glance

  • Drugs Dabigatran etexilate (Primary) ; Apixaban; Rivaroxaban
  • Indications Atrial fibrillation
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Dec 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top